Phentermine vs GLP-1: Full Comparison

Phentermine and GLP-1 drugs suppress appetite through completely different biological pathways.

Phentermine produces faster initial results. Most patients lose 3 to 5% of body weight in the first month, compared to 1 to 3% on GLP-1 drugs. The difference: phentermine's effect plateaus by month 3, while GLP-1 drugs continue producing weight loss for 12 to 18 months.

A systematic review published in JAMA Network Open ranked obesity medications by efficacy: tirzepatide > semaglutide > phentermine-topiramate (Qsymia) > phentermine alone > orlistat. Semaglutide was specifically noted to have "superior efficacy" with "additional cardiometabolic benefits" compared to phentermine.

For detailed week-by-week timelines, see our tirzepatide before and after results and our semaglutide before and after guide.

The cost difference is the primary reason phentermine still has a market despite lower efficacy.

Phentermine is 10x to 50x cheaper than GLP-1 drugs on a monthly basis. A full 12-week course of phentermine costs less than a single month of brand-name Wegovy.

This cost gap explains why phentermine remains the most prescribed weight loss drug in America despite producing less weight loss. For patients without insurance coverage for GLP-1 drugs, phentermine may be the only affordable pharmaceutical option. The December 2025 approval of oral Wegovy at approximately $149 per month narrows this gap. See our 2026 update section below.

For GLP-1 pricing details, see our tirzepatide cost with insurance guide. For compounded options, see our compound semaglutide with B12 guide.

The side effect profiles are entirely different because the mechanisms are different.

Phentermine's side effects are stimulant-related: insomnia, dry mouth, jitteriness, elevated heart rate. GLP-1 side effects are GI-related: nausea, diarrhea, constipation. GLP-1 drugs carry an FDA boxed warning for thyroid C-cell tumors based on animal data. This risk has not been confirmed in humans but contraindicates use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The practical difference: phentermine side effects are constant for the duration of treatment. GLP-1 side effects are worst during dose escalation (first 4 to 16 weeks) and improve significantly once you reach a stable dose.

For managing GLP-1 side effects, see our guides on semaglutide nausea, semaglutide fatigue, and tirzepatide hair loss.

This is where GLP-1 drugs have the most significant advantage over phentermine.

The SELECT trial (NEJM 2023) demonstrated that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo in patients with obesity and established cardiovascular disease. This is the first obesity drug to show cardiovascular benefit.

Phentermine has no long-term cardiovascular safety data. It increases heart rate and blood pressure, which are risk factors for cardiovascular events. The 12-week prescribing limit exists partly because of these cardiovascular concerns. Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, and history of drug abuse.

Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing, with results expected in 2027.

For patients with cardiovascular risk factors, GLP-1 drugs are clearly preferred over phentermine from a safety standpoint.

Despite lower efficacy, phentermine is the right choice in specific situations.

Cost is the primary barrier. If you cannot afford $200+ per month for GLP-1 drugs and do not have insurance coverage, phentermine at $10 to $50 per month is the only affordable pharmaceutical option. A 12-week course is better than no treatment.

You need a short-term boost. Phentermine can provide rapid initial weight loss (3 to 5% in the first month) to build momentum for lifestyle changes. Some practitioners use it as a bridge while waiting for GLP-1 insurance approval.

GLP-1 GI side effects are intolerable. If nausea, diarrhea, or vomiting from GLP-1 drugs is severe enough to cause discontinuation, phentermine offers appetite suppression through a different pathway without GI side effects.

After GLP-1 discontinuation. A Healio study explored using phentermine as a bridge medication after stopping GLP-1 drugs to slow weight regain. This approach is experimental but reflects clinical interest in phentermine's utility within a broader treatment strategy.

You only need modest weight loss. If your goal is 10 to 15 pounds rather than 50+, phentermine may achieve it in 12 weeks without the commitment and cost of long-term GLP-1 therapy.

GLP-1 drugs are preferred in most clinical scenarios.

You need more than 10% body weight loss. Phentermine rarely produces more than 10% loss. GLP-1 drugs routinely produce 15 to 22%.

You have cardiovascular disease or risk factors. Semaglutide has proven cardiovascular benefit (20% risk reduction). Phentermine may increase cardiovascular risk.

You need long-term treatment. Obesity is a chronic condition. Phentermine is limited to 12 weeks. GLP-1 drugs are designed for indefinite use.

You have type 2 diabetes. GLP-1 drugs improve blood sugar control alongside weight loss. Semaglutide (Ozempic) and tirzepatide (Mounjaro) have FDA approval specifically for T2D. Phentermine does not affect blood sugar.

You want sustained appetite suppression. Phentermine develops tolerance by 8 to 12 weeks. GLP-1 drugs maintain effectiveness indefinitely.

Insurance covers GLP-1. If your insurance covers Wegovy, Zepbound, or Mounjaro, the cost differential disappears. Many plans now cover GLP-1 drugs for obesity.

If GLP-1 treatment is not producing expected results, see our guides on why you may not be losing weight on semaglutide and not losing weight on tirzepatide.

For more on GLP-1 mechanisms and dosing, see our semaglutide dosage chart and tirzepatide dosage chart.

Weight regain occurs with both drug classes, but the patterns differ significantly.

The STEP 1 extension study followed patients who stopped semaglutide after 68 weeks. Within one year, participants regained approximately two-thirds of the weight they had lost. A 2025 meta-analysis of GLP-1 discontinuation studies found a pooled mean weight regain of 5.63 kg (PMC12535773).

Phentermine as a bridge. Recent data from EPIC Research suggests phentermine may help slow weight regain after GLP-1 discontinuation. Patients who lost less than 20 pounds on GLP-1 treatment sometimes lost additional weight after switching to phentermine. This phentermine-bridge strategy is experimental and not FDA-approved for this use (source: Healio 2024).

The weight regain reality reinforces a key point: neither phentermine nor GLP-1 drugs cure obesity. Both suppress appetite while you take them. The difference is that GLP-1 drugs can be used indefinitely while phentermine is limited to 12 weeks.

The FDA approved oral Wegovy (semaglutide 25 mg tablet) in December 2025. It became broadly available in the US in January 2026. This changes the phentermine-versus-GLP-1 comparison in two ways.

The injection barrier disappears. One of phentermine's advantages was convenience: a daily pill versus a weekly injection. Oral Wegovy is also a daily pill (taken on an empty stomach, 30 minutes before the first meal). Patients who avoided GLP-1 drugs due to needle aversion now have an oral alternative with GLP-1-level weight loss.

The cost gap narrows. Oral Wegovy starts at approximately $149 per month without insurance, significantly less than injectable Wegovy ($799-1,349 list price). While still more expensive than generic phentermine ($10-50), the gap is smaller.

The oral GLP-1 option does not eliminate phentermine's role entirely. At $10 to $50 per month, phentermine remains the cheapest prescription weight loss option by a wide margin. For patients where cost is the overriding factor, phentermine is still the most accessible choice.

For more on GLP-1 access options, see our where to buy peptides 2026 guide.